These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18692481)

  • 1. Visualization of SV2A conformations in situ by the use of Protein Tomography.
    Lynch BA; Matagne A; Brännström A; von Euler A; Jansson M; Hauzenberger E; Söderhäll JA
    Biochem Biophys Res Commun; 2008 Oct; 375(4):491-5. PubMed ID: 18692481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining modelling and mutagenesis studies of synaptic vesicle protein 2A to identify a series of residues involved in racetam binding.
    Shi J; Anderson D; Lynch BA; Castaigne JG; Foerch P; Lebon F
    Biochem Soc Trans; 2011 Oct; 39(5):1341-7. PubMed ID: 21936812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam.
    Kaminski RM; Gillard M; Leclercq K; Hanon E; Lorent G; Dassesse D; Matagne A; Klitgaard H
    Epilepsia; 2009 Jul; 50(7):1729-40. PubMed ID: 19486357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the interaction of SV2A with racetams using homology modelling, molecular dynamics and site-directed mutagenesis.
    Lee J; Daniels V; Sands ZA; Lebon F; Shi J; Biggin PC
    PLoS One; 2015; 10(2):e0116589. PubMed ID: 25692762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy.
    van Vliet EA; Aronica E; Redeker S; Boer K; Gorter JA
    Epilepsia; 2009 Mar; 50(3):422-33. PubMed ID: 18717715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solubilization and immunopurification of rat brain synaptic vesicle protein 2A with maintained binding properties.
    Lambeng N; Grossmann M; Chatelain P; Fuks B
    Neurosci Lett; 2006 May; 398(1-2):107-12. PubMed ID: 16434140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
    Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy.
    Kaminski RM; Matagne A; Leclercq K; Gillard M; Michel P; Kenda B; Talaga P; Klitgaard H
    Neuropharmacology; 2008 Mar; 54(4):715-20. PubMed ID: 18207204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of Approved Drugs with Synaptic Vesicle Protein 2A.
    Danish A; Namasivayam V; Schiedel AC; Müller CE
    Arch Pharm (Weinheim); 2017 Apr; 350(3-4):. PubMed ID: 28220535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Gillard M
    Epilepsia; 2017 Feb; 58(2):255-262. PubMed ID: 28012162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays.
    Daniels V; Wood M; Leclercq K; Kaminski RM; Gillard M
    Br J Pharmacol; 2013 Jul; 169(5):1091-101. PubMed ID: 23530581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
    Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H
    Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SV2A and SV2C contain a unique synaptotagmin-binding site.
    Schivell AE; Mochida S; Kensel-Hammes P; Custer KL; Bajjalieh SM
    Mol Cell Neurosci; 2005 May; 29(1):56-64. PubMed ID: 15866046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of [(3)H]ucb 30889 binding to synaptic vesicle protein 2A in the rat spinal cord.
    Lambeng N; Gillard M; Vertongen P; Fuks B; Chatelain P
    Eur J Pharmacol; 2005 Sep; 520(1-3):70-6. PubMed ID: 16125696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A New SV2A Ligand for Epilepsy.
    Rogawski MA
    Cell; 2016 Oct; 167(3):587. PubMed ID: 27768878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The human synaptic vesicle protein, SV2A, functions as a galactose transporter in Saccharomyces cerevisiae.
    Madeo M; Kovács AD; Pearce DA
    J Biol Chem; 2014 Nov; 289(48):33066-71. PubMed ID: 25326386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression patterns of synaptic vesicle protein 2A in focal cortical dysplasia and TSC-cortical tubers.
    Toering ST; Boer K; de Groot M; Troost D; Heimans JJ; Spliet WG; van Rijen PC; Jansen FE; Gorter JA; Reijneveld JC; Aronica E
    Epilepsia; 2009 Jun; 50(6):1409-18. PubMed ID: 19220410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levetiracetam but not valproate inhibits function of CD8+ T lymphocytes.
    Li G; Nowak M; Bauer S; Schlegel K; Stei S; Allenhöfer L; Waschbisch A; Tackenberg B; Höllerhage M; Höglinger GU; Wegner S; Wang X; Oertel WH; Rosenow F; Hamer HM
    Seizure; 2013 Jul; 22(6):462-6. PubMed ID: 23639870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Sands ZA; Vandenplas C; Gillard M
    Epilepsia; 2018 Sep; 59(9):e147-e151. PubMed ID: 30144048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioural phenotyping reveals anxiety-like features of SV2A deficient mice.
    Lamberty Y; Detrait E; Leclercq K; Michel A; De Ryck M
    Behav Brain Res; 2009 Mar; 198(2):329-33. PubMed ID: 19041904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.